| 前收盘价格 | 147.40 |
| 收盘价格 | 146.70 |
| 成交量 | 4,728,955 |
| 平均成交量 (3个月) | 7,317,118 |
| 市值 | 220,754,083,840 |
| 预期市盈率 (P/E Forward) | 149.25 |
| 价格/销量 (P/S) | 6.89 |
| 股市价格/股市净资产 (P/B) | 8.31 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2025 - 11 Aug 2025 |
| 营业毛利率 | -9.40% |
| 营业利益率 (TTM) | 0.99% |
| 稀释每股收益 (EPS TTM) | -2.19 |
| 季度收入增长率 (YOY) | 48.60% |
| 总债务/股东权益 (D/E MRQ) | 28.49% |
| 流动比率 (MRQ) | 1.96 |
| 营业现金流 (OCF TTM) | 212.02 M |
| 杠杆自由现金流 (LFCF TTM) | -120.68 M |
| 资产报酬率 (ROA TTM) | -3.22% |
| 股东权益报酬率 (ROE TTM) | -11.44% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | BEIGENE | - | - |
AIStockmoo 评分
0.4
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.38 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| BEIGENE | 221 B | - | - | 8.31 |
| INNOCARE | 30 B | - | - | 3.19 |
| HENLIUS | 24 B | - | 26.46 | 8.48 |
| EVEREST MED | 19 B | - | - | 3.78 |
| ASCENTAGE-B | 17 B | - | - | 86.39 |
| INNOVENT BIO | 126 B | - | - | 8.83 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Growth |
| 内部持股比例 | 4.57% |
| 机构持股比例 | 16.05% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合